| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Settlement of lease | 5,798 | 5,798 |
| Other current assets | -8,997 | -7,697 |
| Other assets | -20,711 | -20,711 |
| Accounts payable | 165,220 | 121,462 |
| Accrued payroll and payroll taxes | 410,758 | 317,113 |
| Other current liabilities | 2,190 | 1,666 |
| Net cash used in operating activities | -646,208 | -446,882 |
| Advance from shareholder | - | 0 |
| Repayments of advance from shareholder | - | 0 |
| Proceeds from short-term convertible notes | 706,635 | 425,197 |
| Proceeds from short-term promissory notes | 13,000 | 10,000 |
| Net cash provided by financing activities | 719,635 | 435,197 |
| Net increase in cash | 73,427 | -11,685 |
| Cash and cash equivalents at beginning of period | 12,144 | - |
| Cash and cash equivalents at end of period | 85,571 | - |
Sigyn Therapeutics, Inc. (SIGY)
Sigyn Therapeutics, Inc. (SIGY)